Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GRCE

Grace Therapeutics Inc

May 01 • 04:00PM ET

2.34

+0.10 4.46 %

Healthcare • Biotechnology • USA • Nano • NASD

Held by: VTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	27.06%	Shs Outstand	15.47M	Perf Week	1.74%
Market Cap	36.21M	Forward P/E	-	EPS next Y	-0.62	Insider Trans	0.00%	Shs Float	11.29M	Perf Month	-52.05%
Enterprise Value	17.54M	PEG	-	EPS next Q	-0.23	Inst Own	22.18%	Short Float	17.26%	Perf Quarter	-35.54%
Income	-5.98M	P/S	-	EPS this Y	-4.43%	Inst Trans	-3.79%	Short Ratio	2.77	Perf Half Y	-25.24%
Sales	0.00M	P/B	0.56	EPS next Y	24.85%	ROA	-9.22%	Short Interest	1.95M	Perf YTD	-32.37%
Book/sh	4.19	P/C	1.94	EPS next 5Y	53.39%	ROE	-10.22%	52W High	5.18 -54.83%	Perf Year	-13.65%
Cash/sh	1.21	P/FCF	-	EPS past 3/5Y	20.89% 44.08%	ROIC	-9.21%	52W Low	1.79 30.73%	Perf 3Y	-14.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.31% 20.94%	Perf 5Y	-90.11%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	70.83%	Oper. Margin	-	ATR (14)	0.48	Perf 10Y	-96.54%
Dividend Ex-Date	-	Quick Ratio	14.96	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	32.05	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.96	EPS Q/Q	62.14%	SMA20	-32.06%	Beta	0.32	Target Price	8.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-40.63%	Rel Volume	1.14	Prev Close	2.24
Employees	-	LT Debt/Eq	0.00	Earnings	Feb 12 BMO	SMA200	-31.94%	Avg Volume	702.57K	Price	2.34
IPO	May 06, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	50.00% -	Trades		Volume	801,812	Change	4.46%

Date	Action	Analyst	Rating Change	Price Target Change
May-02-25	Initiated	TD Cowen	Buy	$12
Sep-01-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-20	Upgrade	B. Riley FBR	Neutral → Buy	$2
Jan-13-20	Downgrade	B. Riley FBR	Buy → Neutral
Aug-29-19	Initiated	B. Riley FBR	Buy	$7.75
Jul-18-19	Initiated	Oppenheimer	Outperform	$7
Jun-26-19	Initiated	H.C. Wainwright	Buy	$6

Apr-23-26 01:13PM	Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 (GlobeNewswire) -45.48%
Apr-14-26 08:00AM	Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 (GlobeNewswire) +12.04%
Mar-19-26 08:00AM	Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences (GlobeNewswire)
Feb-25-26 08:00AM	Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-12-26 08:00AM	Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Nov-17-25 08:00AM	Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference (GlobeNewswire)
Nov-13-25 08:00AM	Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update (GlobeNewswire)
Nov-11-25 08:30AM	Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting (GlobeNewswire)
Oct-23-25 08:00AM	Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review (GlobeNewswire)
Sep-22-25 08:00AM	Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting (GlobeNewswire)
Sep-18-25 08:30AM	Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 (GlobeNewswire)
Sep-04-25 08:00AM	Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-27-25 08:00AM	Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 (GlobeNewswire)
Aug-12-25 08:00AM	Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update (GlobeNewswire)
Jun-25-25 08:00AM	Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 (GlobeNewswire)
08:00AM	Loading…
Jun-23-25 08:00AM	Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update (GlobeNewswire)
Jun-13-25 08:00AM	Grace Therapeutics to Participate in the 2025 BIO International Conference (GlobeNewswire)
Apr-09-25 08:00AM	Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104 (GlobeNewswire) +9.09%
Mar-11-25 07:00AM	Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Feb-25-25 08:00AM	Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -7.19%
Feb-13-25 08:00AM	Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Feb-11-25 10:26AM	Grace Therapeutics secures $15m for GTx-104 pre-commercial development (Pharmaceutical Technology)
Feb-10-25 12:05PM	Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study (Benzinga) +8.33%
08:05AM	Grace Therapeutics Announces Private Placement Financing of up to $30 Million (GlobeNewswire)
08:01AM	Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (GlobeNewswire)
Jan-07-25 08:00AM	Grace Therapeutics to Participate in Upcoming Investor Events January 2025 (GlobeNewswire)
Dec-04-24 08:00AM	Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference (GlobeNewswire) +20.00%
Nov-13-24 08:00AM	Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Oct-30-24 08:00AM	Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024 (GlobeNewswire)
Oct-25-24 08:00AM	Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. (GlobeNewswire)
07:30AM	Loading…
Sep-25-24 07:30AM	Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 (GlobeNewswire) +19.53%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) +12.43%
Sep-12-24 08:00AM	Acasti to Present at the Life Sciences Investor Forum (GlobeNewswire) -8.38%
Sep-05-24 10:35AM	Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-09-24 02:52PM	ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025 (InvestorPlace)
08:00AM	Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Jul-10-24 09:40AM	Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-27-24 04:05PM	Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial (GlobeNewswire)
Jun-21-24 01:53PM	ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024 (InvestorPlace)
08:00AM	Acasti Announces Year-End 2024 Financial Results, Provides Business Update (GlobeNewswire)
Jun-18-24 12:31PM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
May-28-24 04:05PM	Acasti Pharma to Attend BIO International Convention 2024 (GlobeNewswire)
May-23-24 06:45AM	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom (InvestorPlace)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Feb-12-24 08:00AM	Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +6.53%
07:57AM	Acasti: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Feb-01-24 08:00AM	Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial (GlobeNewswire)
Dec-13-23 08:00AM	Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024 (GlobeNewswire)
Nov-13-23 08:20AM	Acasti: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Acasti Announces Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Oct-23-23 08:00AM	Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial (GlobeNewswire)
Oct-04-23 08:00AM	Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH) (GlobeNewswire)
Sep-26-23 08:00AM	Acasti Announces $7.5 Million Private Placement Equity Financing (GlobeNewswire) +35.39%
Sep-06-23 08:00AM	Acasti to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-23-23 03:49AM	TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised) (Zacks)
Aug-22-23 09:19AM	TEVA to Pay $250 Million to Settle Price-Fixing Charges (Zacks)
Aug-11-23 07:10AM	Acasti: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Acasti Announces First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Aug-09-23 04:05PM	Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting (GlobeNewswire)
Jul-28-23 08:02AM	Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates (Zacks)
Jul-10-23 09:00AM	Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients (PR Newswire) -9.55%
Jul-07-23 08:00AM	Acasti Pharma Announces 1-for-6 Reverse Stock Split (PR Newswire) -12.52%
Jul-05-23 09:00AM	Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 (PR Newswire) +18.77%
Jun-23-23 07:00AM	Acasti Pharma Reports Fiscal Year 2023 Operational Results (PR Newswire)
Jun-22-23 09:00AM	Acasti Announces Appointment of New Scientific Advisory Board Members (PR Newswire)
May-17-23 09:00AM	Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
May-10-23 07:41AM	We're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash Wisely (Simply Wall St.)
May-08-23 07:00AM	Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025 (PR Newswire)
Apr-04-23 08:01AM	Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND (PR Newswire)
08:00AM	Acasti Announces Appointment of Prashant Kohli as CEO (PR Newswire)
Mar-30-23 08:30AM	Acasti Pharma Inc. Announces the Resignation of a Director (PR Newswire)
06:57AM	When Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit? (Simply Wall St.)
Mar-13-23 08:00AM	Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange (PR Newswire)
Mar-08-23 09:00AM	Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Mar-04-23 08:28AM	We're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash Wisely (Simply Wall St.)
Feb-28-23 01:00PM	Acasti Pharma Recognizes Rare Disease Day (PR Newswire)
09:40AM	Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-15-23 04:02PM	Acasti Pharma Inc. (NASDAQ:ACST) Q3 2023 Earnings Call Transcript (Insider Monkey)
Feb-14-23 07:00AM	Acasti Pharma Reports Third Quarter 2023 Operational Results (GlobeNewswire)
Feb-07-23 09:00AM	Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 (PR Newswire)
Jan-25-23 09:00AM	Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule (GlobeNewswire)
Jan-24-23 04:15PM	Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31 (GlobeNewswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE) +5.63%
08:45AM	Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast (Newsfile)
Jan-13-23 09:00AM	Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18 (GlobeNewswire)
Jan-05-23 09:00AM	Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures (GlobeNewswire) +18.32%
Dec-29-22 06:02AM	Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript (Insider Monkey)
Dec-28-22 08:00AM	Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Companys Drug Candidate for the Treatment of Ataxia Telangiectasia (GlobeNewswire) +11.09%
Dec-22-22 08:00AM	Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Companys Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN) (GlobeNewswire) +11.99%
Nov-14-22 07:00AM	Acasti Pharma Reports Second Quarter 2023 Operational Results (GlobeNewswire)
Nov-09-22 04:15PM	Acasti Pharma to Present at Q4 Investor Summit (GlobeNewswire)
Nov-07-22 04:15PM	Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022 (GlobeNewswire) -6.01%
Sep-30-22 09:00AM	Acasti Announces Court Dismissal of Stockholder Litigation (GlobeNewswire)
Sep-29-22 09:00AM	Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders (GlobeNewswire)
Sep-21-22 08:45AM	Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast (Newsfile)
Sep-14-22 04:15PM	Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference (GlobeNewswire)
Sep-13-22 08:00AM	Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Companys Drug Candidate for the Treatment of Ataxia Telangiectasia (GlobeNewswire)
Sep-12-22 09:00AM	Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 01:00PM	Edited Transcript of ACST.V earnings conference call or presentation 11-Aug-22 5:00pm GMT (Thomson Reuters StreetEvents)

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GRCE

Grace Therapeutics Inc

Upgrade your Finviz experience